



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_28234
Title of the Manuscript:	Survivin as a Prognostic Marker in Leukemic Egyptian Patients
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	General comments This manuscript describes the expression of survivin, LDH isozymes, vitamin E, vitamin C and malondialdehyde (MDA) in the patients with CLL and ALL. The study demonstrated that expression of survivin, LDH and MDA is elevated in the blood of the cases with CLL and ALL. In contrast, vitamin C level was decreased in ALL and CLL patients. Survivin expression was associated with MDA in the cases with CLL and ALL, whereas its expression was negatively correlated with vitamin C. Although the authors claimed that increased survivin protein was associated with increased risk of leukemia, no data is shown to support this statement in this manuscript. Specific comments Major 1. The title says that Survivin as a prognostic marker in leukemic Egyptian patients; however, this study does not demonstrate any data on the patients' prognosis at all. The title needs to be changed. 2. In the abstract, it is stated that increased survivin protein was associated with increased risk of leukemia; however, no data to support this statement is shown in this manuscript. 3. The blood survivin was analysed using flow cytometry in this study. The authors need to specify the cells in which survivin expression was analysed.	The statement "Increased survivin protein was associated with increased risk of leukemia; because it is a highly significant increase in ALL and CLL patients. Therefore it may be considered as prognostic marker in leukemia." Replaced by the following . "Survivin may play a key role in tumor angiogenesis so, it has an important role in the development of acute and chronic leukemia and it could serve as a significant prognostic marker." 1. New title: Assessment of Survivin and Lactate Dehydrogenase Isoenzyme in Leukemic Egyptian Patients 2. Abstract Survivin may play a key role in tumor angiogenesis so, it has an important role in the development of acute and chronic leukemia 3. Done in subject and methods (line 124) survivin was analysed in Human peripheral blood lymphocytes



SDI Review Form 1.6

	4. The data presented in this manuscript, such as elevation of surivin and LDH are confirmatory of the previous findings. Therefore, it not clear what novelty this study add.	4. The correlation between parameters first studied in the Egyptian patients In our study.
<u>Minor</u> REVISION comments	Ethical issue: The statement for the approval by the IRB should be included.	The statement for the approval is included in line 100 and 101.
<u>Optional/General</u> comments		